ArticleInternational urology and nephrology2026
Water vapor thermal therapy for patients with large prostates (≥ 80 mL): initial real-world data from China.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the safety and efficacy of water vapor thermal therapy (WVTT) in Chinese patients with large prostates (≥ 80 mL).
methodsA retrospective analysis was conducted on patients with large prostates (≥ 80 mL) who underwent WVTT between January 2023 and September 2024. Symptom scores, including the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), and IPSS Quality of Life (QoL), along with clinical outcomes, were assessed.
resultsA total of 57 patients (mean age: 73.88 ± 8.71 years; mean prostate volume: 109.27 ± 27.74 mL) were analyzed. Prostatic median lobe was identified in 64.91% (37/57) of patients. The mean surgical time was 29.13 ± 17.36 min, with 12.98 ± 2.19 vapor injections per patient. At 3 months after surgery, 39 patients completed the follow-up. Significant improvements were observed, including a 51.31% reduction in IPSS (p < 0.001) and a 56.50% improvement in IPSS QoL (p < 0.001). Patients with a prostatic median lobe were younger (mean age: 71.97 ± 8.94 vs. 77.40 ± 7.04 years, p = 0.041) and required more vapor injections (13.43 ± 1.95 vs. 12.11 ± 2.36, p = 0.040). No Clavien-Dindo grade III complications occurred, and the surgical re-treatment rate was 5.13% (2/39).
conclusionsWVTT resulted in significant improvements in symptoms and quality of life for Chinese patients with large prostates, with low re-treatment rates and minimal complications at the 3-month follow-up. Larger cohorts and longer follow-up are needed for further evaluation.
Indexed as
Identifiers
40658145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.